BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 227,357 | 66,502 | 124,841 | 95,590 |
| Depreciation and amortization expense | 41,144 | 35,984 | 37,284 | 68,418 |
| Share-based compensation expenses | 123,355 | 123,761 | 140,809 | 246,287 |
| Gain on deconsolidation of a subsidiary | NaN | NaN | NaN | 0 |
| Acquired in-process research and development | NaN | 0 | 191 | 500 |
| Amortization of research and development cost share liability | -28,645 | -26,251 | -29,275 | -45,569 |
| Impairment of equity investments | NaN | 75,626 | NaN | NaN |
| Loss on long-term investments | NaN | -596 | NaN | NaN |
| Non-cash interest expense | NaN | 14,872 | NaN | NaN |
| Deferred income tax expense | NaN | 9,469 | NaN | NaN |
| Impairment of equity investments | NaN | NaN | 34,216 | NaN |
| Gain on bms termination settlement | NaN | 0 | NaN | NaN |
| Non-cash interest expense | 21,096 | NaN | NaN | NaN |
| Other items, net | 6,172 | -12,548 | -5,533 | 15,128 |
| Accounts receivable | 75,300 | -2,340 | 93,925 | 73,369 |
| Inventories | 71,838 | 70,506 | 28,836 | -6,174 |
| Other assets | -15,270 | 18,083 | -100,563 | 45,316 |
| Accounts payable | -42,187 | 87,214 | 28,471 | -35,852 |
| Accrued expenses and other payables | -16,819 | 145,876 | 90,261 | 75,625 |
| Deferred revenue | NaN | 1,293 | NaN | NaN |
| Other liabilities | 1,731 | 15,418 | 3,486 | 64 |
| Purchase of intangible assets | NaN | 0 | 0 | 20,000 |
| Net cash provided by operating activities | 201,336 | 417,347 | 402,553 | 307,680 |
| Purchase of long-term investments | NaN | 11,834 | NaN | NaN |
| Proceeds from sale or maturity of short-term investments | NaN | 1,646 | 0 | 1,800 |
| Purchases of property, plant and equipment | 40,789 | 37,522 | 48,084 | 100,233 |
| Proceeds from sale or maturity of investments | 27 | NaN | NaN | NaN |
| Purchase of in-process research and development | 0 | 0 | 691 | 60,000 |
| Other investing activities | 4,748 | -9,375 | 499 | 10,113 |
| Net cash used in investing activities | -45,510 | -38,335 | -49,274 | -188,546 |
| Proceeds from sale of future royalties | NaN | 26,000 | 885,000 | NaN |
| Proceeds from long-term loan | NaN | 850,586 | 0 | 0 |
| Repayment of long-term loan | 7,641 | 14,618 | 4,263 | 16,799 |
| Proceeds from short-term loans | 58,204 | 12,155 | 0 | 221,521 |
| Repayment of short-term loans | 0 | 768,999 | 0 | 275,782 |
| Payments of debt issuance costs | NaN | 23,392 | NaN | NaN |
| Payments of withholding taxes from share-based awards | NaN | 0 | 0 | 24,195 |
| Repayment of sale of future royalties liability | 2,557 | 4,044 | NaN | NaN |
| Proceeds from option exercises and employee share purchase plan | 23,875 | 19,243 | 80,535 | 96,503 |
| Other financing activities | -3,249 | 0 | 0 | 0 |
| Net cash provided by (used in) financing activities | 68,632 | 96,931 | 961,272 | 1,248 |
| Effect of foreign exchange rate changes, net | 19,320 | 23,162 | 9,905 | 26,957 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 243,778 | 499,105 | 1,324,456 | 147,339 |
| Cash, cash equivalents, and restricted cash at beginning of period | 4,609,647 | 4,110,542 | 2,638,747 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 4,853,425 | 4,609,647 | 4,110,542 | NaN |